Rocket Lab stock (NASDAQ: RKLB) suffered a sharp selloff on October 15 after the company confirmed that its highly anticipated Neutron rocket would not make its first flight in 2026. The revised timeline pushed the inaugural launch into 2027, disappointing investors who had been counting on the next-generation rocket to accelerate the company’s expansion into the larger commercial and government launch markets.
Shares plunged as much as 13% during early trading, while prominent Wall Street analysts responded by cutting their price targets. KeyBanc lowered its target from $135 to $100, and Clear Street reduced its estimate from $129 to $105. Both firms, however, maintained their positive investment ratings, suggesting that the setback has not fundamentally erased their longer-term optimism about Rocket Lab’s prospects.
The delay raises an important question for investors: Is the latest decline a temporary reaction to a development setback, or does it signal deeper challenges for Rocket Lab’s growth strategy?
The answer depends largely on how quickly the company resolves its manufacturing issues, completes the remaining qualification tests and demonstrates that Neutron can become a reliable contributor to future revenue.
Rocket Lab Stock Slides as Neutron Launch Moves to 2027
Rocket Lab shares fell to approximately $51.42 during the October 15 session, according to Proactive Investors, before recovering some ground. At 12:58 p.m. Eastern time, the stock was trading at $52.72, down 10.92% on the day.
The decline followed an already difficult session on Wednesday, October 14, when RKLB shares dropped 7.85% to close at $59.18. After the market closed, the company disclosed the revised Neutron launch schedule, sending shares down approximately 6% in after-hours trading, Reuters reported.
The announcement triggered a particularly strong reaction because Neutron is central to Rocket Lab’s ambitions to move beyond its established small-satellite launch business.
While the company’s Electron rocket has helped establish its position in the space industry, Neutron is intended to open opportunities in larger payload launches, satellite constellation deployment and government missions. Delaying that expansion means investors will have to wait longer for evidence that the new vehicle can deliver on its commercial potential.
The market reaction also highlights how closely Rocket Lab’s valuation is tied to expectations for future growth rather than just its existing business performance.
Manufacturing Defects Force Rocket Lab to Revise Neutron’s Timeline
Rocket Lab confirmed on October 14 that Neutron’s inaugural flight is now expected in 2027, following the discovery of manufacturing defects in the forward dome of the rocket’s first-stage propellant tank.
The component is made from carbon-fibre composite material and forms part of the structure designed to contain the rocket’s propellant. During inspections, engineers identified voids within the composite, raising concerns that the affected section might not meet the required performance margins.
Chief Executive Peter Beck said the company investigated the issue, reproduced the defect during testing and implemented changes to its manufacturing process. Subsequent work on another composite component, the aft dome, showed improved manufacturing quality.
That progress is encouraging, but it does not mean the rocket is ready for launch.
The forward dome must still be completed and qualified before Rocket Lab can finish the remaining tests on the first-stage propellant tank. The company expects cryogenic and hydrostatic qualification testing to extend into the first quarter of 2027.
These tests are essential for demonstrating that the tank can withstand the pressures and conditions associated with its intended operating environment. Until they are successfully completed, Rocket Lab cannot establish a firm timetable for Neutron’s first flight.
The latest delay follows another setback in January 2026, when a first-stage tank ruptured during pressure testing. That incident led Rocket Lab to shift its original launch target to the fourth quarter of 2026.
The company has not attributed the newly identified forward-dome manufacturing defects to the earlier tank rupture. Nevertheless, the two setbacks underscore the technical and manufacturing challenges involved in bringing a new launch vehicle to operational readiness.
For investors, the immediate priority is to see whether the corrected manufacturing process produces consistent results and allows the qualification program to advance without further major interruptions.
KeyBanc and Clear Street Cut Their Rocket Lab Price Targets
The revised launch schedule prompted Wall Street analysts to reassess their expectations for Rocket Lab shares.
KeyBanc analyst Michael Leshock cut his 12-month price target to $100 from $135, a reduction of approximately 26%. Despite the lower valuation, he maintained an Overweight rating on the stock.
According to Investing.com, the revised outlook reflects expectations for one fewer revenue-generating Neutron launch in 2027, alongside lower valuation multiples across high-growth space companies.
Clear Street analyst Gregory Pendy also reduced his price target, lowering it to $105 from $129, a decrease of nearly 19%. He retained his Buy rating.
The adjustments illustrate how sensitive Rocket Lab’s valuation is to changes in Neutron’s development schedule. When a major growth project slips, anticipated revenue can move further into the future, affecting financial forecasts and the value investors assign to those future earnings.
However, neither analyst abandoned a positive rating. Their decisions suggest that the revised timeline has weakened near-term expectations without necessarily invalidating the longer-term investment case.
Cantor Fitzgerald took a more optimistic stance, reiterating its $122 price target and Overweight rating on October 15. Its bullish outlook reflects the potential for Neutron to compete in the medium-lift launch market, where SpaceX’s Falcon 9 is an established player.
The contrast between these assessments shows that analysts remain divided on the near-term implications of the delay, even as some continue to see substantial opportunities for Rocket Lab over time.
Rocket Lab’s decline was also considerably steeper than losses across several other publicly traded space companies. During Thursday morning trading, SpaceX and AST SpaceMobile were each down approximately 2%, according to 24/7 Wall St.
Although wider market conditions may have contributed to the selling pressure, the difference suggests that Neutron’s revised schedule was a major driver of the reaction in RKLB shares.
Why Neutron Is So Important to Rocket Lab’s Growth Strategy
Neutron is designed to carry approximately 13,000 kilograms to low Earth orbit, giving Rocket Lab access to a substantially larger payload market than the one served by its Electron rocket.
The vehicle is expected to support satellite constellation deployments, national-security missions and other launches requiring greater lifting capacity. These opportunities could expand Rocket Lab’s addressable market and help it compete for contracts that fall outside Electron’s capabilities.
The commercial significance extends beyond the first launch itself.
A successful debut would represent an important technical milestone, but sustained operations and repeat missions would be necessary for Neutron to become a meaningful source of revenue. The longer development takes, the longer Rocket Lab must continue funding manufacturing, infrastructure and qualification work before the program can begin delivering operational launch income.
That creates a difficult balance for investors. They must weigh the potential long-term rewards of a larger launch vehicle against the additional costs, execution risks and uncertainty associated with its development.
Still, Rocket Lab is not relying exclusively on Neutron to sustain its business.
In the second quarter of 2026, the company reported revenue of $234.1 million, representing 62% year-over-year growth. Its contracted backlog also reached $2.36 billion, providing evidence of demand across its existing operations and broader space business.
These figures offer important context for evaluating the stock. Although Neutron is a major part of Rocket Lab’s expansion strategy, its existing business provides an established commercial foundation while development continues.
The Electron program remains particularly relevant. In September, Rocket Lab announced a multiyear agreement covering 20 additional Electron missions for Japanese Earth observation company Synspective.
That contract supports the company’s small-launch operations independently of Neutron’s launch schedule and demonstrates why the distinction between Rocket Lab’s current business and its future ambitions matters.
Strong revenue growth and a substantial backlog do not eliminate the risks associated with Neutron, but they help explain why some analysts remain constructive despite the latest setback.
What Rocket Lab Investors Should Watch Next
Following the selloff, the next meaningful developments will come from Neutron’s manufacturing and testing program rather than another preliminary launch estimate.
Several milestones deserve particular attention.
1. Completion of the forward dome
Rocket Lab must finish manufacturing the affected component and demonstrate that it meets the required specifications. Evidence that the revised production process consistently delivers acceptable results would help address concerns about further manufacturing delays.
2. First-stage tank qualification
The company must complete the remaining assembly and qualification work, including cryogenic and hydrostatic testing expected to extend into early 2027. Successful completion would provide a clearer indication of Neutron’s readiness for its first flight.
3. Capital spending and cash consumption
Investors should examine upcoming quarterly results for changes in capital expenditure, cash usage and the financial resources required to bring Neutron to launch readiness. Additional development time could increase the period during which the program requires funding before generating launch revenue.
4. Revenue growth and contracted demand
Rocket Lab’s existing operations remain important indicators of its ability to support continued investment. Revenue trends, contracted launch work and backlog developments can help investors assess the strength of the business while Neutron remains under development.
These factors are especially important given the volatility RKLB shares have experienced throughout 2026. Previous trading declines have demonstrated how quickly investor expectations can change when the company’s growth plans encounter obstacles.
The latest reaction reinforces that sensitivity. Even with strong revenue growth and a sizeable backlog, delays affecting a strategically important project can have an outsized impact on the stock.
Is Rocket Lab Stock Still Worth Watching After the Selloff?
Rocket Lab’s latest setback has weakened near-term expectations, but it has not ended the company’s ambitions for Neutron.
KeyBanc and Clear Street have reduced their price targets to reflect the revised schedule and valuation pressures, yet both have maintained positive ratings. Cantor Fitzgerald has also reiterated its bullish outlook, highlighting the continuing disagreement over how much of the long-term opportunity remains intact.
For investors, the key distinction is between a delayed development program and a failed commercial strategy. Rocket Lab has identified a manufacturing problem and says it has implemented corrective measures, but those changes must still be validated through the remaining qualification process.
The company’s existing revenue base, expanding backlog and continued Electron contracts provide reasons to monitor its progress. At the same time, further testing problems, higher development costs or additional schedule changes could put renewed pressure on the stock.
The bottom line: Rocket Lab has confirmed that Neutron will not fly in 2026, and no specific inaugural launch date has been announced for 2027. Until the forward dome is completed and the first-stage tank passes its remaining qualification tests, uncertainty surrounding the launch timetable is likely to remain a major factor in RKLB’s valuation.
For now, investors will have to look beyond analyst price targets and focus on tangible engineering progress. The next successful testing milestones may offer a more meaningful signal of Neutron’s prospects than any new launch estimate.
